Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05747053 · ClinicalTrials.gov registry record
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
A clinical trial, sponsored by George Washington University.
- Terminated
- Registry status
- 105
- Enrollment target
NCT05747053 is a clinical trial that was terminated before completion, run by George Washington University. The registered enrollment target is 105 participants.
The verdict
NCT05747053 was terminated before completion, sponsored by George Washington University.
- TERMINATED
- Registry status
- 105 participants
- Enrollment target
Study Summary
Long-term graft failure rates continue to be unacceptably high despite the development of immunosuppressive drugs, underscoring the unmet need for robust prognostic biomarkers of allograft injury and failure. While rates of acute rejection (AR) continue to decrease, it remains the strongest predictor of long-term allograft survival, and so having a better understanding of factors predicting AR may contribute to more individualized patient care. Selecting optimum immunosuppressive dosage is another factor in personalizing kidney care. This project will study two areas of individualized kidney care: 1) assessing rejection by surveillance testing utilizing AlloSure, 2) developing an algorithm to select optimum immunosuppressive medication dosage.
Interventions
- DIAGNOSTIC_TEST AlloSure
- DIAGNOSTIC_TEST PAXGene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2022-12-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05747053
The ClinicalTrials.gov registry entry for NCT05747053 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AlloSure is the first listed.
NCT05747053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05747053 about?
NCT05747053 is a clinical study titled "Personalization of Immunosuppressive Treatment for Organ Transplant Recipients". Long-term graft failure rates continue to be unacceptably high despite the development of immunosuppressive drugs, underscoring the unmet need for robust prognostic biomarkers of allograft injury and failure. While rates of acute rejection (AR) continue to decrease, it remains the strongest predicto...
What is the current status of trial NCT05747053?
This trial is currently terminated. The enrollment target is 105 participants. The study started on 2020-10-01. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT05747053?
The interventions under investigation include: AlloSure (DIAGNOSTIC_TEST), PAXGene (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05747053?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.